Literature DB >> 18184409

Homeoprotein Cdx2 and nuclear PTEN expression profiles are related to gastric cancer prognosis.

Zhigang Bai1, Yingjiang Ye, Dingbao Chen, Danhua Shen, Feng Xu, Zhirong Cui, Shan Wang.   

Abstract

The aim of the study was to analyze the expression of Cdx2 and nuclear PTEN in relation to clinicopathological features of gastric cancer tissue biopsies in order to determine the value of a combined analysis of Cdx2 and nuclear PTEN expression in distinguishing histological types and prognosis of gastric cancers. The expression of Cdx2 and nuclear PTEN was studied using immunohistochemistry of paraffin-embedded tumor specimens from 99 patients who underwent radical D2 gastrectomy between 1999 and 2001. Cdx2 and nuclear PTEN expression were detected in 39.6% (36 of 91) and 70.3% (64 of 91) of gastric cancer cases, respectively. There was a negative correlation between Cdx2 expression and Lauren classification (p=0.032), and between nuclear PTEN expression and lymph node metastasis (p=0.049). Patients with Cdx2-positive, or nuclear PTEN-positive expression had higher survival rates than those with Cdx2-negative or nuclear PTEN-negative expression (p<0.001 and p=0.003, respectively). Co-expression of Cdx2 and nuclear PTEN showed significantly lower levels in diffuse- or mixed-type cancers than in intestinal-type cancers (p=0.005). Multivariate analysis revealed that Cdx2 expression was an independent prognostic indicator of gastric cancer (p=0.014). These data suggest that combined analysis of Cdx2 and nuclear PTEN expression can have significant value in distinguishing histological types of gastric cancer and assessing prognosis in patients with gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18184409     DOI: 10.1111/j.1600-0463.2007.00654.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  6 in total

1.  AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor.

Authors:  Juinn-Lin Liu; Zhenyu Mao; Gary E Gallick; W K Alfred Yung
Journal:  Neuro Oncol       Date:  2010-12-01       Impact factor: 12.300

2.  CDX2 is involved in microRNA-associated inflammatory carcinogenesis in gastric cancer.

Authors:  Motonobu Saito; Hirokazu Okayama; Katsuharu Saito; Jin Ando; Kensuke Kumamoto; Izumi Nakamura; Shinji Ohki; Yoshimasa Ishi; Seiichi Takenoshita
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

3.  Prognostic significance of Cdx2 immunohistochemical expression in gastric cancer: a meta-analysis of published literatures.

Authors:  Xiao-Tong Wang; Wei-Yuan Wei; Fan-Biao Kong; Chao Lian; Wen Luo; Qiang Xiao; Yu-Bo Xie
Journal:  J Exp Clin Cancer Res       Date:  2012-11-26

4.  CDX2 inhibits invasion and migration of gastric cancer cells by phosphatase and tensin homologue deleted from chromosome 10/Akt signaling pathway.

Authors:  Yong-Qiang Liu; Zhi-Gang Bai; Xue-Mei Ma; Zhong-Tao Zhang
Journal:  Chin Med J (Engl)       Date:  2015-04-20       Impact factor: 2.628

5.  Poorly Differentiated Medullary Phenotype Predicts Poor Survival in Early Lymph Node-Negative Gastro-Esophageal Adenocarcinomas.

Authors:  Christoph Treese; Pedro Sanchez; Patricia Grabowski; Erika Berg; Hendrik Bläker; Martin Kruschewski; Oliver Haase; Michael Hummel; Severin Daum
Journal:  PLoS One       Date:  2016-12-28       Impact factor: 3.240

6.  Loss and reduced expression of PTEN correlate with advanced-stage gastric carcinoma.

Authors:  Xuehua Zhu; Xia Qin; Maogui Fei; Wenmin Hou; Joel Greshock; Kurtis E Bachman; Jiuhong Kang; Crystal Ying Qin
Journal:  Exp Ther Med       Date:  2012-10-15       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.